AAAAAA

   
Results: 1-2 |
Results: 2
COMPARISONS BETWEEN IN-VITRO AND IN-VIVO METABOLISM OF (S)-WARFARIN -CATALYTIC ACTIVITIES OF CDNA-EXPRESSED CYP2C9, ITS LEU(359) VARIANT AND THEIR MIXTURE VERSUS UNBOUND CLEARANCE IN PATIENTS WITH THE CORRESPONDING CYP2C9 GENOTYPES
Authors: TAKAHASHI H KASHIMA T NOMOTO S IWADE K TAINAKA H SHIMIZU T NOMIZO Y MURAMOTO N KIMURA S ECHIZEN H
Citation: H. Takahashi et al., COMPARISONS BETWEEN IN-VITRO AND IN-VIVO METABOLISM OF (S)-WARFARIN -CATALYTIC ACTIVITIES OF CDNA-EXPRESSED CYP2C9, ITS LEU(359) VARIANT AND THEIR MIXTURE VERSUS UNBOUND CLEARANCE IN PATIENTS WITH THE CORRESPONDING CYP2C9 GENOTYPES, Pharmacogenetics, 8(5), 1998, pp. 365-373
METABOLISM OF WARFARIN ENANTIOMERS IN JAPANESE PATIENTS WITH HEART-DISEASE HAVING DIFFERENT CYP2C9 AND CYP2C19 GENOTYPES
Authors: TAKAHASHI H KASHIMA T NOMIZO Y MURAMOTO N SHIMIZU T NASU K KUBOTA T KIMURA S ECHIZEN H
Citation: H. Takahashi et al., METABOLISM OF WARFARIN ENANTIOMERS IN JAPANESE PATIENTS WITH HEART-DISEASE HAVING DIFFERENT CYP2C9 AND CYP2C19 GENOTYPES, Clinical pharmacology and therapeutics, 63(5), 1998, pp. 519-528
Risultati: 1-2 |